Sperm Protein 17: Clinical Relevance of a Cancer/Testis Antigen, from Contraception to Cancer Immunotherapy, and Beyond

Chiriva‐Internati, Maurizio

doi:10.3109/08830185.2011.569903

Cited by 16 publications

(11 citation statements)

References 69 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure shows that the splenocytes from placebo‐treated mice contained SP17 specific T‐cells, although at a lower frequency compared with those from the vaccine group. This was expected, since it was shown that, being SP17 a highly immunogenic antigen, spontaneous SP17‐specific responses can arise in vivo and such pre‐existing SP17‐specific T cells can be stimulated ex vivo, although in the absence of a vaccination strategy such the one we tested here, they are likely inefficient in controlling the growth of malignant cells.…”

Section: Discussionmentioning

confidence: 73%

“…Due to this tumor‐restricted pattern of expression combined with their strong in vivo immunogenicity, CTAs represent ideal targets for tumor‐specific immunotherapeutic strategies. As an example, the small (17.4 kDa) antigenic CTA, sperm protein 17 (SP17), highly expressed in spermatozoa and largely conserved between mouse and human (94% homology), is aberrantly expressed in multiple cancers of unrelated histological origins, including OC, multiple myeloma (MM), nervous system tumors, as well as lung and esophageal cancers, among others . Our work has previously demonstrated that SP17‐specific CD8+ cytotoxic T lymphocytes (CTL) are capable to kill MM cells presenting SP17 epitopes on major histocompatibility complex (MHC) class I molecules .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

Mattila¹,

Mirandola²,

Chiriva‐Internati

2018

J Biomed Mater Res

View full text Add to dashboard Cite

Although it only accounts for approximately 5% of all female cancer cases, ovarian cancer (OC) ranks as the fifth leading cause of death due to cancer in women. We have evaluated the potential of an orally administered microparticulate vaccine incorporating an immunodominant epitope peptide derived from the cancer/testis antigen sperm protein 17 (SP17) aberrantly expressed in OC, to retard the progression of the disease. The peptide antigen and the immune-stimulatory toll-like receptor 9 ligand CpG oligonucleotide were incorporated into spray dried microparticles composed of enteric and sustained release polymers together with the Aleuria aurantia lectin targeting microfold cells present in the gut-associated lymphoid tissue. These particles were administered via oral route to mice challenged week prior with SP17-expressing ID8 OC cells. Analysis of splenocytes harvested from vaccinated mice revealed strong activation of IFN-γ+/CD8+ lymphocytes in response to re-stimulation with the SP17 antigen. Moreover, vaccinated animals showed significant retardation of ascites/tumor volume in comparison to placebo-treated animals four weeks after the tumor challenge (p = 0.005). Taken together, our results suggest that vaccination against SP17 using orally administered microparticles could potentially be used as an effective consolidation strategy for OC patients with residual tumor or high probability for relapse following first-line treatments. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2018.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

Mattila¹,

Mirandola²,

Chiriva‐Internati

2018

J Biomed Mater Res

View full text Add to dashboard Cite

show abstract

“…Here, we propose a different model in which Notch signaling and CTA expression interact to maintain a self-replicating MM cell population. Although CTA expression has been described in a broad range of solid and hematologic malignancies [33,35,36,39,40,41,43], MM is distinct in that a significant majority of patients express AKAP-4 and/or SP17 in their tumor cells [34,37,38,42]. No other type of cancer has such a close association with specific CTA expression pattern.…”

Section: Interactions Between Notch Signaling and Cta Expression In Tmentioning

confidence: 99%

Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis

Colombo

Mirandola²,

Reidy

et al. 2015

International Reviews of Immunology

Self Cite

View full text Add to dashboard Cite

Tumor initiating cells (TICs) differ from normal stem cells (SCs) in their ability to initiate tumorigenesis, invasive growth, metastasis and the acquisition of chemo and/or radio-resistance. In the last years, several studies have indicated the potential role of the Notch system as a key regulator of cellular stemness and tumor development.Furthermore, the expression of cancer testis antigens (CTA) in TICs, and their role in SC differentiation and biology, has become an important area of investigation. Here we propose a model in which CTA expression and Notch signaling interacts to maintain the sustainability of self-replicating tumor populations, ultimately leading to the development of metastasis, drug resistance, and cancer progression. We hypothesize that Notch-CTA interactions in TICs offer a novel opportunity for meaningful therapeutic interventions in cancer.

show abstract

“…Several investigators have since demonstrated that various malignant tumors of unrelated histological origin express Sp17, including multiple myeloma [14], ovarian cancer [15][16][17][18][19][20], esophageal squamous cell carcinomas [21], endometrial and cervical cancers [22], esthesioneuroblastomas [23], and several other subtypes of human nervous system tumors [24]. Some authors have proposed that the role of Sp17 in transformed cells is to promote cell-to-cell and cell-to-matrix adhesion, in this way contributing to motility and migration in cancer cells [25,26].…”

mentioning

confidence: 99%

Sperm Protein17 is an Oncofetal Antigen: A Lesson From a Murine Model

Arnaboldi¹,

Menon²,

Menegola³

et al. 2014

International Reviews of Immunology

Self Cite

View full text Add to dashboard Cite

Sperm protein 17 (Sp17) was originally identified in the flagellum of spermatozoa and subsequently included in the subfamily of tumor-associated antigens known as cancer-testes antigens (CTA). Sp17 has been associated with the motility and migratory capacity in tumor cells, representing a link between gene expression patterns in germinal and tumor cells of different histological origins. Here we review the relevance of Sp17 expression in the mouse embryo and cancerous tissues, and present additional data demonstrating Sp17 complex expression pattern in this murine model. The expression of Sp17 in embryonic as well as adult neoplastic cells, but not normal tissues, suggests this protein should be considered an "oncofetal antigen." Further investigations are necessary to elucidate the mechanisms and functional significance of Sp17 aberrant expression in human adult cells and its implication in the pathobiology of cancer.

show abstract

Sperm Protein 17: Clinical Relevance of a Cancer/Testis Antigen, from Contraception to Cancer Immunotherapy, and Beyond

Cited by 16 publications

References 69 publications

Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis

Sperm Protein17 is an Oncofetal Antigen: A Lesson From a Murine Model

Contact Info

Product

Resources

About